A Phase III Study of Levoketoconazole versus Placebo to Treat Endogenous Cushing's Syndrome


Full Title

COR-2017-01: A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome


In people with a disorder known as Cushing’s syndrome, levels of the hormone cortisol are very high in the urine and blood. Lowering cortisol levels relieves the symptoms and complications of Cushing’s syndrome.

In this study, researchers are comparing the safety and effectiveness of the investigational drug levoketoconazole with a placebo (inactive drug) in patients with endogenous Cushing’s syndrome. Levoketoconazole is a tablet that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have newly diagnosed, persistent, or recurrent Cushing’s syndrome that cannot be cured with surgery.
  • An acceptable amount of time must have passed between the completion of prior therapies and entry into the study, to allow for a sufficient “washout” period.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Eliza Geer at 646-888-2627.